Abstract. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a promising candidate for cancer treatment, but some cancer cell types are resistant to TRAIL cytotoxicity. Therefore, overcoming this resistance is necessary for effective TRAIL therapy. Mitochondrial morphology is important for the maintenance of cell function and survival, and is regulated by the delicate balance between fission and fusion. However, the role of mitochondrial morphology dynamics in TRAIL-induced apoptosis is unknown. Here we show that mitochondrial division inhibitor-1 (mdivi-1), an inhibitor of dynamin-related protein1 (Drp1), modulates mitochondrial morphology and TRAIL-induced apoptosis in human cancer cells. mdivi-1 treatment (≥12.5 µM) caused dose-and time-dependent cell death in malignant melanoma, lung cancer and osteosarcoma cells, while sparing normal cells. mdivi-1 also sensitized cancer cells to TRAIL-induced apoptosis. This potentiation of apoptosis occurred through a caspase-depependent mechanism including the mitochondrial and endoplasmic reticulum (ER) stress pathways. Mdivi-1 potentiated mitochondrial oxidative stress, a major cause of mitochondrial and ER stresses, as evidenced by increases in mitochondrial reactive oxygen species levels, mitochondrial mass, and cardiolipin oxidation. Live cell fluorescence imaging using MitoTracker Red CMXRos revealed that Mdivi-1 caused substantial mitochondrial hyperfusion. Moreover, silencing of Drp1 expression also caused mitochondrial hyperfusion and sensitized cancer cells to TRAIL-induced apoptosis. Our results suggest that cancer cells are more vulnerable than normal cells to a perturbation in mitochondrial morphology dynamics and that this higher susceptibility can be exploited to selectively kill cancer cells and sensitize to TRAIL.
Introduction
Apo2 ligand/tumor necrosis factor (TNF)-related apoptosis-inducing ligand (Apo2L/TRAIL), a member of the TNF superfamily, has emerged as a promising candidate for cancer therapy on the basis of its capacity to induce apoptosis in various types of cancer cells without significant cytotoxicity toward normal cells (1) (2) (3) (4) . Binding of TRAIL to two death receptors (DRs), TRAIL receptor (TRAIL-R)1/DR4 and TRAIL-R2/DR5 triggers the extrinsic and intrinsic apoptotic pathways (5, 6) . However, some cancer cell types such as melanoma, non-small cell lung cancer and osteosarcoma are resistant to TRAIL, despite expressing DRs (7, 8) . Moreover, TRAIL-responsive tumors acquire resistance rendering TRAIL therapy ineffective. Thus, drugs that overcome this resistance are urgently needed for effective TRAIL therapy.
Mitochondria are highly dynamic organelles with a reticular organization that is regulated by the balance between fission and fusion. Mitochondrial morphology is critical for cell function and survival (9, 10) . The mitochondrial network depends on the delicate balance between two antagonistic machineries responsible for fission and fusion of the mitochondrial membrane. Disruption of mitochondrial fission leads to an extensively interconnected and collapsed mitochondrial network, while defects in mitochondrial fusion lead to mitochondrial fragmentation and loss of mitochondrial DNA (11) . Mitochondrial fission helps to eliminate damaged mitochondria through autophagy (mitophagy) (12) . On the other hand,
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mitochondrial fusion facilitates the exchange of mitochondrial DNA and metabolites required for mitochondrial function (13) . Efficient mitochondrial fusion is important for cell viability, because cells defective in fusion exhibit reduced growth, decreased mitochondrial membrane potential (∆Ψ m ), and defective respiration (14) . Mitochondrial fusion and fission in mammalian cells are controlled by dynamin-related proteins with GTPase activity, namely mitofusin 1/2 (Mfn1/2), optic atrophy 1 and dynamin-related protein 1 (Drp1). Mfn1/2, and optic atrophy 1 act in concert to regulate mitochondrial fusion and cristae organization, while Drp1 regulates mitochondrial fission (14, 15) . Controversial results have been reported on the role of mitochondrial fission in cancer cell apoptosis. Mitochondrial fission has been shown to act as both pro-apoptotic and anti-apoptotic events in cancer cell apoptosis, depending on the cell types and the apoptotic stimuli applied (16) (17) (18) (19) (20) (21) (22) . At present, there is no model that can depict the dual functions of mitochondrial fission in cancer cell apoptosis. Mitochondrial division inhibitor-1 (mdivi-1) was recently identified as a potent inhibitor of Drp1 GTPase in yeast and mammalian cells (23) . To gain insight into the role of mitochondrial morphology dynamics in cancer cell apoptosis, we examined whether mdivi-1 affected mitochondrial morphology and TRAIL-induced apoptosis. we found that mdivi-1 killed different cancer cell types including malignant melanoma, lung cancer and osteosarcoma cells, while sparing normal cells. mdivi-1 treatment also sensitized cancer cells to TRAIL-induced apoptosis. This potentiation of apoptosis by mdivi-1 occurred through activation of mitochondrial and endoplasmic reticulum (ER) pathways by increasing mitochondrial oxidative stress, a major cause of these pathways.
Materials and methods
Reagents. Soluble recombinant human TRAIL and mdivi-1 were obtained from Enzo Life Sciences (San Diego, CA, USA). Thapsigargin, rotenone, antimycin A, oligomycin and carbonyl cyanide p-trifluoromethoxyphenylhydrazone (FCCP) were obtained from Sigma-Aldrich (St. Louis, MO, USA). The general caspase inhibitor z-VAD-fluoromethylketone (FMK), caspase-3/7-specific inhibitor z-DEVD-FMK, caspase-8-specific inhibitor z-IETD-FMk, and caspase-9-specific inhibitor z-LEHD-FMk were purchased from Merck Japan. The reagents were dissolved in dimethylsulfoxide and diluted with Hanks' balanced salt solution (HBSS) (pH 7.4) to a final concentration of <0.1% before use.
Cell culture. The human melanoma cell lines, human A549 lung cancer cells, osteosarcoma cell lines, and human fetal fibroblastlike lung wI-38-40 cells were obtained from Health Science Research Resource Bank (Osaka, Japan). These cell lines were cultured in Dulbecco's modified Eagle's medium (DMEM; Sigma-Aldrich) supplemented with 10% fetal bovine serum (FBS; Sigma-Aldrich) in a 5% CO 2 incubator. Normal human epidermal melanocytes were obtained from Cascade Biologics and cultured in DermaLife Basal Medium supplemented with DermaLife M LifeFactors (kurabo, Osaka, Japan). Cells were harvested by incubation in 0.25% trypsin-ethylenediaminetetraacetic acid (Life Technologies Japan) for 5 min at 37˚C.
Cell viability and apoptosis measurements. Cell viability was measured with wST-8 assay using the Cell Counting kit (Dojindo, kumamoto, Japan), a colorimetric assay based on the formation of a water-soluble formazan product. Cells (1x10 3 /well) were seeded in 96-well plates and cultured with the agents to be tested for 72 h at 37˚C in a 5% CO 2 incubator. Then 1/10 volume of wST-8 reagent was added, incubated for 1 h at 37˚C and absorbance at 450 nm was measured using a microplate reader (ARVO MX, Perkin Elmer, Japan). Apoptotic cell death was quantitatively assessed by doublestaining with fluorescein isothiocyanate (FITC)-conjugated Annexin V and propidium iodide (PI) as previously described (24) . Briefly, cells (2x10 5 /well) in 24-well plates were incubated with the agents to be tested for 24 h in 10% FBS-containing medium at 37˚C. Subsequently, the cells were stained with FITC-conjugated Annexin V and PI using a commercially available kit (Annexin V FITC Apoptosis Detection kit I; BD Biosciences, Japan). The stained cells were evaluated in the FACSCalibur and analyzed using CellQuest software (BD Biosciences 4 /well) in DMEM were placed on coverslips (Asahi Glass Co, Tokyo, Japan) and treated with the agents to be tested for 24 h at 37˚C in a 5% CO 2 incubator. After removing the medium, the cells were washed and stained with 20 nM MitoTracker Red CMXRos and Hoechst 33342 (Dojindo) in HBSS for 1 h at 37˚C in the dark in a 5% CO 2 incubator. The cells were then washed with HBSS and immersed in HBSS to prevent cell damage. Low magnification images were obtained with a fluorescence microscope (IX71 inverted microscope, Olympus, Tokyo, Japan) and analyzed using LuminaVision software (Mitani Corporation, Fukui, Japan). High magnification images were gained and analyzed with EVOS FL Cell Imaging System (Life Technologies Japan).
Caspase-3/7 activation and ∆Ψ m measurements. Activation of caspase-3/7 and changes in ∆Ψ m were simultaneously measured by flow cytometry as previously described (24) . Briefly, cells (2x10 5 /ml) in 24-well plates were treated with the agents to be tested for 24 h in 10% FBS/DMEM at 37˚C and then stained with the dual sensor MitoCasp TM kit (Cell Technology, Mountain View, CA, USA). Caspase-3/7 activation and ΔΨ m were evaluated using FACSCalibur, and the data were analyzed using CellQuest software.
Caspase-12 activation assay. Activation of caspase-12 in living cells was measured using the caspase-12 inhibitor ATAD-FMk conjugated to FITC (FITC-ATAD-FMk) as previously described (24) . FITC-ATAD-FMk is cell-permeable and non-toxic and binds irreversibly to active caspase-12, but not inactive caspase-12, in apoptotic cells. Briefly, cells (2x10 5 /ml) in 24-well plates were treated with the agents to be tested for 24 h in 10% FBS/DMEM at 37˚C and then stained with a CaspGlow TM Fluorescein Active Caspase-12 Staining kit (BioVision, Mountain View, CA, USA). Fluorescence was determined using the FL-1 channel of FACSCalibur and analyzed using CellQuest software.
Determination of surface DR4/DR5 expression. DR4 and DR5 expression on the cell surface was assessed by flow cytometry as previously described (25) . Briefly, cells (5x10 5 /100 µl) were incubated with monoclonal anti-human DR4 and DR5 antibodies or mouse isotype-matched control antibodies (R&D Systems, Minneapolis, MN, USA) for 30 min at 4˚C. The cells were then centrifuged into a pellet, resuspended in phosphate-buffered saline (PBS), and then incubated with phycoerythrin-conjugated goat F(ab') 2 anti-mouse IgG (R&D Systems) for 30 min at 4˚C. The fluorescence was measured using the FL-2 channel of FACSCalibur and analyzed using CellQuest software.
Mitochondrial oxidative stress measurements. Mitochondrial oxidative stress was measured by monitoring mitochondrial ROS production using MitoSOX TM Red (Life Technologies Japan) by flow cytometry and the signals were calibrated as previously described (26) . Briefly, cells (5x10 5 /500 µl) suspended in HBSS were incubated with the agents to be tested for 4 h at 37˚C and then incubated with 5 µM MitoSOX for 15 min at 37˚C for loading. The cells were washed, resuspended in HBSS on ice, centrifuged at 4˚C and analyzed for their fluorescence. Mitochondrial oxidative stress was also assessed by measuring oxidation of cardiolipin by flow cytometry using the fluorescent dye 10-N-nonyl acridine orange (NAO, Life Technologies Japan), which binds to nonoxidized cardiolipin, but not oxidized cardiolipin, as previously described (26) . Briefly, cells (5x10 5 /500 µl) suspended in HBSS were incubated with the agents to be tested for 4 h at 37˚C and then incubated with 100 nM NAO for 15 min at 37˚C. The cells were washed and resuspended in HBSS on ice, and fluorescence was analyzed. Red fluorescence (MitoSOX) and green fluorescence (NAO) were measured using the FL-2 and FL-1 channel, respectively, of FACSCalibur and analyzed using CellQuest software. The data were expressed as F/F 0 , where F 0 is the fluorescence of unstimulated cells and F is the fluorescence of stimulated cells.
Drp1 gene silencing by siRNA. Mitochondrial fission was inhibited by downregulating Drp1 expression using small interfering RNA. Cells (2.5x10 5 /well) were plated in 6-well plates and transfected with 20 nM each of Drp1-targeting siRNA or scrambled control siRNA (Santa Cruz Biotechnology, Santa Cruz, CA, USA) using Lipofectamine RNA/Max kit (Life Technologies Japan) according to the manufacturer's instructions and cultured for 72 h at 37˚C in a 5% CO 2 incubator. The downregulation of Drp1 protein levels was assessed by immunoblotting.
Immunoblotting. The levels of Drp1, pro-caspase and cleaved caspase-3 proteins were determined using immunoblotting. For the analysis of Drp1 protein levels, cells (1x10 6 /ml) were washed with PBS, and lysed with RIPA buffer containing protease inhibitors. Whole cell lysates (30 µg protein) were subjected to reducing sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) using a 10% separation gel (ATTO Co., Tokyo, Japan) and transferred onto polyvinylidene difluoride membranes (Nippon Millipore, Tokyo, Japan). The membranes were blocked with BlockAce (Dainippon Sumitomo Pharma, Osaka, Japan) for 1 h at room temperature, washed with PBS containing 0.1% Tween-20, then incubated with anti-Drp1 antibody (Santa Cruz Biotechnology) overnight at 4˚C followed by incubation with horseradish peroxidase (HRP)-conjugated species-specific anti-rabbit Ig (GE Healthcare Japan, Tokyo, Japan) for 1 h at room temperature. After washing, immunoreactive proteins were detected using the ECL Prime kit (GE Healthcare Japan). For the analysis of caspase-3 protein levels, cells (1x10 6 /ml) in 10% FBS/DMEM were treated with the agents to be tested for the indicated times, washed with PBS and lysed with RIPA buffer. Whole cell lysates (15 µg protein) were separated by SDS-PAGE using 4-12% gradient gel (Life Technologies Japan) and transferred onto Immobilon-P membranes (Nippon Millipore). The membranes were blocked with Blocking-One (Nacalai Tesque, Tokyo, Japan) overnight at 4˚C, and then incubated with anti-caspase-3 or anti-cleaved caspase-3 antibodies (Cell Signaling Technology Japan) overnight at 4˚C, followed by incubation with HRP-conjugated secondary antibody (GE Healthcare Japan) for 1 h at room temperature. After washing in PBS containing 0.1% Tween-20, immunoreactive bands were visualized with Chemi-Lumi One Super (Nacalai Tesque). To verify equal loading, the membranes were re-probed with monoclonal anti-GAPDH (Santa Cruz Biotechnology) or anti-β-actin antibody (Sigma-Aldrich).
Statistical analysis. Data were analyzed by one-way analysis of variance followed by the post-hoc Tukey's test. All values were expressed as mean ± SE, and P<0.05 was considered to be significant.
Results

Mdivi-1 reduces cell viability and sensitizes cancer cells to TRAIL cytotoxicity.
we examined the ability of mdivi-1 to affect cell viability in human cancer cells. For this purpose, we utilized different cancer cell types with different sensitivities to TRAIL: the human malignant melanoma cell lines A375 and GAk and the human lung cancer cell line A549. Cells were treated with mdivi-1 and TRAIL alone or in combination for 24-72 h, and cell viability was measured using wST-8 assay. In all cell lines tested, mdivi-1 alone up to 50 µM only modestly decreased cell viability in the initial 24 h. However, mdivi-1 (≥12.5 µM) caused a robust decrease in cell viability at 72 h in a dose-dependent manner (Fig. 1A-C) . GAk cells, which were relatively sensitive to TRAIL cytotoxicity, were also sensitive to mdivi-1 (maximum of 40% decrease at 50 µM). Moreover, mdivi-1 markedly sensitized these cells to TRAIL cytotoxicity during the initial 24 h (data not shown) and this effect became increasing prominent over another 48 h (Fig. 1A-C) . The human osterosarcoma cell lines MG63, HOS and G292 were relatively resistant to TRAIL, because treatment with 100 ng/ml TRAIL for 72 h resulted in only a modest decrease (maximum of 30%) in cell viability. In contrast, mdivi-1 alone dose-dependently decreased cell viability in all these cell lines. In addition, mdivi-1 markedly potentiated TRAIL cytotoxicity (Fig. 1D-F) . This effect was clearer in TRAIL-sensitive cells (MG63) than in TRAIL-resistant cells (HOS and G292). These results show that mdivi-1 decreases cell viability and sensitizes cancer cells to TRAIL cytotoxicity.
mdivi-1 potentiates DR4/5-mediated apoptosis in cancer cells.
To clarify the mode of cell death potentiated by mdivi-1, A375 cells were analyzed for Annexin V and propidium iodide (PI) double staining by flow cytometry. Fig. 2A shows typical results. mdivi-1 up to 25 µM alone induced minimal increase in Annexin V + cells but enhanced the increase by TRAIL, indicating that mdivi-1 sensitizes these cells to TRAIL-induced apoptosis. This sensitization was dosedependent with a minimal effective dose of 12.5 µM and was clearly observed with TRAIL (≥25 ng/ml) ( Fig. 2A and B) . In contrast, as previously reported by others (27) , thapsigargin up to 1 µM was ineffective at inducing apoptosis, and mdivi-1 did not potentiate the effect ( Fig. 2A and C) . mdivi-1 also sensitized the cells to apoptosis induced by the anti-DR5 or DR4 agonist antibodies (Fig. 2D) , suggesting that the sensitization mainly occurs through increased DR4/DR5 apoptotic signaling. Similarly, mdivi-1 substantially sensitized A549 cells to TRAIL-induced apoptosis (Fig. 2E) . TRAIL up to 100 ng/ml minimally increased the number of necrotic (Annexin V -/PI + ) cells (<2.5%), and mdivi-1 did not significantly increase this cell population in either of the two cell types, indicating that necrotic cell death plays a minor role in the potentiation effect. In contrast, MG63 cells displayed robust basal necrotic cell death (11.1±2.4%, n=3), which was increased by TRAIL up to 16%, while mdivi-1 decreased it. Interestingly, as basal necrotic cell death increased, apoptosis was induced to a lesser extent in response to TRAIL and/or mdivi-1, suggesting a negative effect of necrotic cell death on apoptosis rate. Collectively, these results show that mdivi-1 potentiates DR4/5-mediated cell death in different human cancer cell types. Potentiation of apoptosis by mdivi-1 occurs through a caspase-dependent pathway. Because of their easy handling, high responsivity to mdivi-1, and the availability of normal counterparts, we used A375 and A549 cells as models for investigating the molecular mechanisms underlying the potentiation effect of mdivi-1. To elucidate the possible role of the caspase cascade, we examined the effects of an array of caspase inhibitors on the potentiation mediated by mdivi-1. The general caspase inhibitor z-VAD-FMk completely abolished the potentiation of apoptosis in A375 cells, indicating that the effect is caspase-dependent (Fig. 3A) . The caspase-8-specific inhibitor z-IETD-FMK, the caspase-9-specific inhibitor z-LEHD-FMk and the caspase-3/7-specific inhibitor z-DEVD-FMK all abolished the potentiation of apoptosis almost completely, suggesting the involvement of both the extrinsic and intrinsic death pathways in the potentiation (Fig. 3A) . Similar results were obtained with A549 cells except that the caspase-8 and caspase-9 inhibitors were less effective than the caspase-3 inhibitor (Fig. 3B) . These results show that the potentiation of apoptosis occurs through a caspase-dependent pathway involving caspase-3 activation. To provide insight into the mechanisms underlying the potentiation, we examined the effects of TRAIL and mdivi-1 on ∆Ψ m and caspase-3 activation, because loss of ∆Ψ m impairs mitochondrial integrity disruption, resulting in the release of pro-apoptotic factors and caspase-3 activation. Simultaneous measurements using a ∆Ψ m -specific dye and a caspase-3-specific substrate revealed that TRAIL induced substantial ∆Ψ m dissipation and caspase-3 activation in A375 cells in a dose-dependent manner within 24 h (Fig. 3C) . Although mdivi-1 up to 50 µM alone caused only modest loss of ∆Ψ m and caspase-3 activation, it markedly potentiated the effects of TRAIL (Fig. 3C-E) . In contrast, mdivi-1 had little effects on ∆Ψ m or caspase-3 activation induced by thapsigargin (Fig. 3C) . Immunoblotting provided additional evidence for the potentiation of TRAIL-induced caspase-3 activation by Mdivi-1. Mdivi-1 or TRAIL alone induced minimal cleavage of procaspase-3 (p32), while the combination of TRAIL and mdivi-1 caused a robust increase in levels of cleaved (active) caspase-3 (p17/p12). The cleaved caspase-3 was first detected at 8 h after stimulation and levels continued to increase for another 4 h. Thereafter levels decreased probably due to additional processing (Fig. 3F) . These results show that the potentiation of apoptosis by mdivi-1 occurs through a caspase-dependent pathway including the intrinsic pathway.
Potentiation of apoptosis by mdivi-1 is mediated by caspase-12 activation.
To explore the role of ER death pathway in the potentiation of apoptosis by mdivi-1, we examined the ability of mdivi-1 to modulate activation of caspase-12, an ER-associated caspase, which occurs independently of the extrinsic and intrinsic death pathways. Measurements of caspase-12 activity using a specific substrate revealed that basal caspase-12 activation was low (1.46±0.19%, n=3), and 100 ng/ml TRAIL and 50 µM mdivi-1 individually induced caspase-12 activation to a similar extent (10.4 and 15.4%, respectively). However, synergistic effects were observed when these two agents were used together (59.9%) (Fig. 4A) . Next, we examined the effect of z-ATAD-FMK, a caspase-12-specific inhibitor, on apoptosis. TRAIL-induced apoptosis was strongly (maximum of 60%) inhibited by z-ATAD-FMk, while z-LEVD-FMk, an inhibitor of another ER-associated enzyme, caspase-4, was ineffective (Fig. 4B) . Moreover, the potentiation of TRAILinduced apoptosis by mdivi-1 was completely abolished by treatment with z-ATAD-FMk, while z-LEVD-FMk exhibited only modest (<10%) inhibition (Fig. 4C) . Taken together, these results suggest that potentiation of apoptosis by mdivi-1 is mediated by caspase-12 activation. prerequisite event in apoptosis and caspase-3 activation in human malignant tumor cells induced by diverse pro-apoptotic stimuli including TRAIL (24, (28) (29) (30) (31) . To elucidate the possible role of depolarization in the TRAIL-sensitizing effect of mdivi-1, we examined the ability of mdivi-1 to induce depolarization using the anionic dye bis-oxonol in a flow cytometer. Mdivi-1 alone up to 50 µM caused only modest depolarization. However, mdivi-1 (≥25 µM) potentiated TRAIL-induced depolarization as effectively as 5 µg/ml antimycin A (Fig. 5A ). Since increase in mitochondrial ROS (mROS) levels is a major cause of mitochondrial integrity disruption and the intrinsic pathway, we measured the effect of mdivi-1 on mROS levels using MitoSOX, a fluoroprobe that targets mitochondria and serves as a selective probe for superoxide in these organelles (32, 33) . As shown in Fig. 5B, 25 and 100 ng/ml TRAIL increased MitoSOX fluorescence by 1.5-and 3-fold, respectively, at 4 h. Mdivi-1 alone also robustly increased MitoSOX fluorescence (3-fold). when TRAIL and mdivi-1 were used together, their effects were additive (Fig. 5B) . we also assessed oxidation of cardiolipin, a phospholipid that is associated with cytochrome c in the outer surface of the inner mitochondrial membrane. Because the fluorescent dye NAO binds to non-oxidized cardiolipin, but not to oxidized cardiolipin, measurement of NAO fluorescence can be used to monitor oxidation of cardiolipin in mitochondria (34) . Fig. 5C shows a representative histogram. TRAIL increased oxidation of cardiolipin in a dose-dependent manner, as shown by the decrease in NAO fluorescence (an increase in the M1 population). Although mdivi-1 alone did not affect the oxidation of cardiolipin, it markedly potentiated the effect of TRAIL (Fig. 5C ). In contrast, thapsigargin alone had a minimal effect on the oxidation of cardiolipin, and mdivi-1 only slightly altered the effect of the compound. A considerable increase in NAO fluorescence (an increase in the M2 population) was also observed in cells treated with TRAIL alone or TRAIL+mdivi-1, suggesting an increase in mitochondrial mass. However, unlike the MitoSOX signals and cardiolipin oxidation, the mitochondrial mass changes were not TRAIL dose-dependent. In contrast, thapsigargin had a minimal effect on mitochondrial mass. Collectively, these results show that the potentiation of TRAIL-induced apoptosis by mdivi-1 is preceded by depolarization and increased mitochondrial oxidative stress and mass, all of which are potentiated by the compound.
Potentiation of apoptosis by mdivi-1 is preceded by depolarization and increased mitochondrial oxidative stress and mass. Persistent cell membrane depolarization is an early and
Effects of mdivi-1 are tumor-selective. To examine the effect of mdivi-1 on cell survival, primary melanocytes were treated with TRAIL and/or mdivi-1, and analyzed for Annexin V and PI double staining by flow cytometry. As shown in Fig. 6A , TRAIL and mdivi-1 alone or in combination induced minimal apoptosis in the cells despite robust cell surface expression of DR4 and DR5 (25) . we also examined the effect of TRAIL and/or mdivi-1 on the survival of WI-38 fibroblast-like lung cells. Again, TRAIL and mdivi-1 alone or in combination induced minimal apoptosis in these cells (Fig. 6B) despite substantial cell surface expression of DR5 (Fig. 6C) . Collectively, these findings show that the effects of mdivi-1 are tumor-selective. 
Mdivi-1 exerts its TRAIL-sensitizing effects through the modulation of mitochondrial morphology.
To evaluate the role of mitochondrial morphology dynamics in the TRAIL-sensitizing effect of mdivi-1, we examined its effect on mitochondrial morphology. Cells were loaded with the mitochondria-targeting dye MitoTracker Red and examined under a fluorescence microscope. A reticular network radiating from the nucleus was clearly observed in untreated A375 cells (Fig. 7A) . As expected, marked mitochondrial morphological changes were observed at 24 h after the addition of mdivi-1. Robust mitochondrial hyperfusion with a bias towards one of the poles of the nucleus was observed (Fig. 7A) . Mdivi-1 caused similar mitochondrial hyperfusion in A549 and MG63 cells (Fig. 7B and C) . To examine whether these effects of mdivi-1 are mediated by an ability to modulate mitochondrial fission, we analyzed the impact of Drp1 gene silencing on the mitochondrial morphology, because Drp1 GTPase activity is essential for mitochondrial fission (14, 15) . Treatment with Drp1 siRNA for 72 h resulted in a marked decrease in Drp1 protein expression compared with control cells treated with a control siRNA (Fig. 7D,  left panel) . In the Drp1 knockdown cells, prominent mitochondrial hyperfusion was observed, as in mdivi-1-treated cells (Fig. 7E) . Moreover, Drp1 knockdown by itself did not increase basal apoptosis, while A375 and A549 Drp1 knockdown cells were more susceptible than control cells to TRAIL-induced apoptosis, and this sensitization became more apparent as TRAIL concentrations increased (Fig. 7F  and G) . The effects of Drp1 knockdown were specific for TRAIL, because it had minimal effects on cellular sensitivity to thapsigargin in either cell type (Fig. 7F and G) . These results show that mdivi-1 sensitizes cancer cells to TRAIL by modulating mitochondrial morphology.
Discussion
In this study we demonstrate for the first time that mdivi-1 kills and sensitizes different human cancer cell types to TRAIL-induced apoptosis. Several lines of evidence indicate that these effects are mediated by mitochondrial morphology modulation: i) After mdivi-1 treatment, marked mitochondrial morphological changes, including mitochondrial hyperfusion with a bias towards a pole of the nucleus, were detected; ii) similar mitochondrial hyperfusion was observed in Drp1 knockdown cells; and iii) Drp1 knockdown also sensitized different cancer cell types to TRAIL-induced apoptosis. Collectively, the present findings indicate that inhibition of mitochondrial fission potentiates apoptosis, suggesting that mitochondrial fission inhibits cancer cell apoptosis. Our findings are similar to previous studies showing that etoposide and arsenic trioxide induce mitochondrial aggregation, an event upstream of cytochrome c release during apoptosis in glioblastoma cells (35, 36) and suggest a universal role for mitochondrial network changes during cancer cell apoptosis.
Healthy mitochondria are required for cell health, and numerous diseases including cancer are associated with aberrant mitochondrial network dynamics (37) . Consequently, drugs that modulate mitochondrial fission and fusion may restore proper dynamics and have therapeutic potential (37) . However, the role of mitochondrial fission in cancer cell apoptosis remains elusive, because controversial results have been reported with regard to its role. Various apoptosis inducers cause extensive fragmentation of mitochondria in cancer cells concomitant with mitochondrial outer membrane permeabilization and cytochrome c release (19, 21) . Moreover, inhibition of mitochondrial fission by downregulation of Drp1 or Fis1, a counterpart of Drp1, has been shown to delay cytochrome c release, suggesting that mitochondrial fission is important for apoptosis (16, 17, 20) . In contrast, other studies have revealed that Drp1-dependent mitochondrial fragmentation is not a prerequisite for apoptosis and that they are separate events, because mitochondrial fission was neither essential for cytochrome c release nor obligatory for apoptosis (19, 22) . In addition, several lines of evidence suggest that mitochondrial fission is protective against Ca 2+ -induced apoptosis (14) . Human lung cancer cell lines exhibit an imbalance of Drp1/Mfn-2 expression compared with normal human lung epithelial and vascular cells and a state of mitochondrial fragmentation. Lung tumor tissue samples from patients exhibit similar increase in mitochondrial fragmentation compared with normal lung tissue. Consistent with a protective role of mitochondrial fission, inhibition of mitochondrial fragmentation by Drp1 knockdown or mdivi-1 or promotion of mitochondrial fusion by Mfn2 overexpression increases spontaneous apoptosis in lung cancer cells and regress tumor growth in vivo (38) . Our data expand these observations and suggest that mitochondrial fission protects different human cancer cell types including melanoma, lung cancer and osteosarcoma cells from apoptosis. Importantly, mdivi-1 had minimal cytotoxicity and TRAIL-sensitizing effect in normal melanocytes and fibroblasts. This indicates that mdivi-1 may be selectively cytotoxic toward tumor cells. Although the mechanisms underlying this selectivity remain to be elucidated, it is plausible that disruption of mitochondrial morphology dynamics preferentially causes mitochondrial dysfunction in cancer cells.
we found that mdivi-1 potentiates multiple pro-apoptotic events, including membrane depolarization, loss of ∆Ψ m , caspase-3 and caspase-12 activation, mROS generation and cardiolipin oxidation. These observations are in accordance with our previous studies showing that diverse compounds (39) and mitochondrial inhibitors such as antimycin A and FCCP (26) . A loss of ∆Ψ m is the main cause of mitochondrial outer membrane permeabilization, mitochondrial integrity disruption and pro-apoptotic protein release. Mitochondrial outer membrane permeabilization allows release of several pro-apoptotic proteins including cytochrome c and apoptosis-inducing factor-1, thereby promoting the activation of the caspase-9-caspase-3 cascade and processing of key regulatory and structural proteins. Although the precise mechanisms of mitochondrial outer membrane permeabilization are poorly understood, it is widely accepted that an increase in permeabilization of the inner mitochondrial membrane is involved and that mitochondrial permeability transition pores (mPTPs) are thought to play pivotal roles in this process (40, 41) . mPTPs are putative high-conductance non-specific channels in the inner mitochondrial membrane, which are composed of proteins that link the inner and outer mitochondrial membrane. Several mitochondrial proteins localized in these membranes such as voltage-dependent anion channels and adenine nucleotide translocase are thought to constitute the mPTP. It is thought that concurrent opening of multiple mPTPs causes excess mitochondrial swelling, the physical disorganization of the outer mitochondrial membrane, mitochondrial pro-apoptotic protein release and apoptosis (42) . In this regard, it is noteworthy that the potentiation of apoptosis by mdivi-1 was associated with increased mitochondrial mass, a hallmark of mitochondrial swelling. Because adenine nucleotide translocase has three cysteine residues whose oxidation is critical for mPTP opening/ closing, mPTPs are particularly vulnerable to ROS (40, 41, 43) . Consequently, mitochondrial permeability transition can be triggered by excess mROS generation and/or disruption of the mitochondrial redox homeostasis (44) (45) (46) (47) . In addition, mROS can control cytochrome c release through the oxidation of the mitochondrial phospholipid cardiolipin (46) . The enhancement of membrane depolarization may be also important in the potentiation of apoptosis, because persistent depolarization is an early and prerequisite event in TRAIL-induced apoptosis in cancer cells (24, 28) . Importantly, depolarization and mROS mutually control one another. Depolarization potentiates TRAIL-induced mROS generation, while scavenging of mROS by antioxidants reduces depolarization, and mROS generation by mitochondrial metabolic dysfunction potentiates the depolarization (28) . In addition, scavenging of mROS inhibits pro-apoptotic events in the intrinsic and ER death pathways, including ∆Ψ m dissipation, caspase-3 and caspase-12 activation, suggesting that mROS plays a central role in the intrinsic and ER death pathways (48) . Collectively, our data suggest that mitochondrial oxidative stress play a key role in the TRAIL-sensitizing effect of mdivi-1.
In conclusion, the present study shows that cancer cells are more vulnerable than normal cells to disruption of mitochondrial network dynamics and that this higher susceptibility can be exploited in cancer treatment, in particular in combination therapy with TRAIL.
